C8 Health vs Etiometry Platform

The vendor labels its outcome figures for Etiometry observational: length of stay down by up to 36%, ICU readmissions down by up to 41%, ventilation time down by up to 30%. Published work on its indices includes a 2025 Critical Care Medicine paper on vasoactive infusion duration after pediatric cardiac surgery. Etiometry holds eleven 510(k) clearances, the latest K254066 for a Cardiogenic Shock Tool in April 2026. Three of its four risk indices are cleared only for patients up to 12 years old. IDO2 covers post-surgical patients 0 to 12 years weighing 2 kg or more, and adults 18 and older who are not on mechanical circulatory support.

Etiometry suits a pediatric cardiac ICU or critical care service. C8 Health is sold to health systems and its evidence is perioperative: its proof library reports ERAS compliance rising from 65% to 88% in five months at MetroHealth, an internal study reported by the vendor. Neither company posts a price.